Program
emoxypine succinate
Also written as “Mexidol” and “Mexidol (Ethylmethylhydroxypyridine Succinate)”.
Its studies are mostly in Ischemic Stroke · Cognitive Dysfunction · Glaucoma, Open-Angle · Ischemia · Attention Deficit Disorder with Hyperactivity, led by Pharmasoft.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharmasoft | 81 open or running | phase 4since Jan 15, 2024 | May 31, 2016 | Apr 2027phase 4 · NCT07575984 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 31, 2016First study: phase 3 study in Ischemic StrokeFirst studyNCT02793687 · 150 enrolled · Russian Federation
- Jan 15, 2024Phase 4 study in Ischemic StrokeNCT06221826 · 60 enrolled · Russian Federation
- May 24, 2024Phase 3 study in Ischemic StrokeNCT06437626 · 304 enrolled · Kazakhstan, Russia, Uzbekistan
- Feb 11, 20252 phase 3 studiesNCT06854601, NCT06834490
- Mar 24, 2025Phase 2 study in Glaucoma, Open-AngleNCT06903156 · 102 enrolled · Russia
- May 4, 2026Phase 4 study in Ischemic StrokeNCT07575984 · 120 planned · Russia
- Jul 7, 2026Phase 4 study in Cognitive DysfunctionNCT07700615 · 120 enrolled · Russia
Ahead
- Apr 2027Primary completion: phase 4 study in Ischemic StrokeNCT07575984
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07700615Cognitive Dysfunction · Russia | 4 | Completed | Nov 5, 2025 | 120 |
| NCT07575984Ischemic Stroke · Russia | 4 | Recruiting | Apr 2027 | 120 |
| NCT06903156Glaucoma, Open-Angle · Russia | 2 | Completed | Sep 7, 2023 | 102 |
| NCT06854601Attention Deficit Disorder with Hyperactivity · Russia | 3 | Completed | Jul 13, 2020 | 333 |
| NCT06834490Ischemia · Russia, Uzbekistan | 3 | Completed | Dec 8, 2020 | 318 |
| NCT06437626Ischemic Stroke · Kazakhstan, Russia, Uzbekistan | 3 | Completed | Aug 18, 2023 | 304 |
| NCT06221826Ischemic Stroke · Russian Federation | 4 | Completed | Sep 12, 2023 | 60 |
| NCT02793687Ischemic Stroke · Russian Federation | 3 | Completed | May 27, 2016 | 150 |
How it is read
Names in the registry
- “Mexidol”, 7 entries
- “Mexidol (Ethylmethylhydroxypyridine Succinate)”, 1 entry
Conditions, from the studies’ own filings
- Ischemic Stroke, 4 studies
- Cognitive Dysfunction, 1 study
- Glaucoma, Open-Angle, 1 study
- Ischemia, 1 study
- Attention Deficit Disorder with Hyperactivity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.